References
- Global strategy for asthma management and prevention (2018 update) [Internet]. 2018 [cited 2018 Jun 13]. Available from: https://ginasthma.org/wp-content/uploads/2018/04/wms-GINA-2018-report-tracked_v1.3.pdf
- Holgate ST, Wenzel S, Postma DS, et al. Asthma. Nat Rev Dis Primers. Internet]. 2015 [cited 2018 Sep 19];1:15025. Available from http://www.nature.com/articles/nrdp201525
- Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med. Internet]. 2012 [cited 2018 May 9];18:716–725. Available from http://www.nature.com/articles/nm.2678
- Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. Internet]. 2014 [cited 2018 May 9];43:343–373. Available from http://erj.ersjournals.com/cgi/doi/10.1183/09031936.00202013
- Nunes C, Pereira AM, Morais-Almeida M. Asthma costs and social impact. Asthma Res Pract. Internet]. 2017 [cited 2018 May 10];3:1. Available from http://asthmarp.biomedcentral.com/articles/10.1186/s40733-016-0029-3
- Chung KF. Precision medicine in asthma: linking phenotypes to targeted treatments. Curr Opin Pulm Med. Internet]. 2018 [cited 2018 Apr 10];24:4–10. Available from http://insights.ovid.com/crossref?an=00063198-201801000-00003
- Lefaudeux D, De Meulder B, Loza MJ, et al. U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics. J Allergy Clin Immunol. Internet]. 2017 [cited 2018 Aug 8];139:1797–1807. Available from http://www.ncbi.nlm.nih.gov/pubmed/27773852
- Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the severe asthma research program. Am J Respir Crit Care Med. Internet]. 2010 [cited 2019 Jan 16];181:315–323. Available from http://www.ncbi.nlm.nih.gov/pubmed/19892860
- Fitzpatrick AM, Moore WC. Severe asthma phenotypes — how should they guide evaluation and treatment? J Allergy Clin Immunol Pract. Internet]. 2017 [cited 2019 Mar 21];5:901–908. Available from http://www.ncbi.nlm.nih.gov/pubmed/28689840
- Wu W, Bleecker E, Moore W, et al. Unsupervised phenotyping of severe asthma research program participants using expanded lung data. J Allergy Clin Immunol. Internet]. 2014 [cited 2018 May 18];133:1280–1288. Available from http://linkinghub.elsevier.com/retrieve/pii/S0091674914001080
- Fahy JV. Type 2 inflammation in asthma–present in most, absent in many. Nat Rev Immunol. Internet]. 2015 [cited 2018 May 9];15:57–65. Available from http://www.nature.com/articles/nri3786
- Bousquet J, Chanez P, Lacoste JY, et al. Eosinophilic inflammation in asthma. N Engl J Med. Internet]. 1990 [cited 2018 May 10];323:1033–1039. Available from http://www.nejm.org/doi/abs/10.1056/NEJM199010113231505
- Chung KF. Targeting the interleukin pathway in the treatment of asthma. Lancet. Internet]. 2015 [cited 2018 May 17];386:1086–1096. Available from http://linkinghub.elsevier.com/retrieve/pii/S0140673615001579
- Carr TF, Zeki AA, Kraft M. Eosinophilic and Noneosinophilic Asthma. Am J Respir Crit Care Med. Internet]. 2018 [cited 2018 Sep 20];197:22–37. Available from http://www.atsjournals.org/doi/10.1164/rccm.201611-2232PP
- Takatsu K. Interleukin-5 and IL-5 receptor in health and diseases. Proc Jpn Acad Ser B Phys Biol Sci. Internet]. 2011 [cited 2018 Mar 22];87:463–485. Available from http://www.ncbi.nlm.nih.gov/pubmed/21986312
- Dunican EM, Fahy JV. Asthma and corticosteroids: time for a more precise approach to treatment. Eur Respir J. Internet]. 2017 [cited 2018 Sep 21];49:1701167. Available from http://erj.ersjournals.com/lookup/doi/10.1183/13993003.01167-2017
- Sweeney J, Patterson CC, Menzies-Gow A, et al. Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the optimum patient care research database and the british thoracic difficult asthma registry. Thorax. Internet]. 2016 [cited 2019 Jan 16];71:339–346. Available from http://thorax.bmj.com/lookup/doi/10.1136/thoraxjnl-2015-207630
- Pavord ID. Oral corticosteroid-dependent asthma: current knowledge and future needs. Curr Opin Pulm Med. Internet]. 2019 [cited 2019 Jan 16];25:51–58. Available from http://insights.ovid.com/crossref?an=00063198-201901000-00008
- Waljee AK, Rogers MAM, Lin P, et al. Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ. Internet]. 2017 [cited 2019 Jan 16];357:j1415. Available from http://www.bmj.com/lookup/doi/10.1136/bmj.j1415
- Caruso M, Morjaria J, Emma R, et al. Biologic agents for severe asthma patients: clinical perspectives and implications. Intern Emerg Med. Internet]. 2018 [cited 2018 Mar 22];13:155–176. Available from http://www.ncbi.nlm.nih.gov/pubmed/29238905
- Emma R, Morjaria JB, Fuochi V, et al. Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience. Ther Adv Respir Dis. Internet]. 2018 [cited 2018 Nov 16];12:175346661880849. Available from http://www.ncbi.nlm.nih.gov/pubmed/30354852
- Weltman JK, Karim AS. Interleukin-5: a proeosinophil cytokine mediator of inflammation in asthma and a target for antisense therapy. Allergy Asthma Proc. Internet]. 1998 [cited 2018 Sep 26];19:257–261. Available from http://www.ncbi.nlm.nih.gov/pubmed/9801738
- Nussbaum JC, Van Dyken SJ, von Moltke J, et al. Type 2 innate lymphoid cells control eosinophil homeostasis. Nature. Internet]. 2013 [cited 2018 May 17];502:245–248. Available from http://www.ncbi.nlm.nih.gov/pubmed/24037376
- Scanlon ST, McKenzie AN. Type 2 innate lymphoid cells: new players in asthma and allergy. Curr Opin Immunol. Internet]. 2012 [cited 2018 Sep 26];24:707–712. Available from http://www.ncbi.nlm.nih.gov/pubmed/22985480
- Greenfeder S, Umland SP, Cuss FM, et al. Th2 cytokines and asthma. The role of interleukin-5 in allergic eosinophilic disease. Respir Res. Internet]. 2001 [cited 2018 Sep 26];2:71–79. Available from http://www.ncbi.nlm.nih.gov/pubmed/11686868
- Van Straaten JF, Dokter WH, Stulp BK, et al. The regulation of interleukin 5 and interleukin 3 gene expression in human T cells. Cytokine. Internet]. 1994 [cited 2018 Sep 27];6:229–234. Available from http://www.ncbi.nlm.nih.gov/pubmed/7914436
- Umland SP, Razac S, Shah H, et al. Interleukin-5 mRNA stability in human T cells is regulated differently than interleukin-2, interleukin-3, interleukin-4, granulocyte/macrophage colony-stimulating factor, and interferon-gamma. Am J Respir Cell Mol Biol. Internet]. 1998 [cited 2018 Sep 27];18:631–642. Available from http://www.atsjournals.org/doi/abs/10.1165/ajrcmb.18.5.3046
- Kolbeck R, Kozhich A, Koike M, et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol. Internet]. 2010 [cited 2018 May 17];125:1344–1353.e2. Available from http://linkinghub.elsevier.com/retrieve/pii/S0091674910005907
- Lambrecht BN, Hammad H. The immunology of asthma. Nat Immunol. Internet]. 2015 [cited 2018 Sep 28];16:45–56. Available from http://www.ncbi.nlm.nih.gov/pubmed/25521684
- Varricchi G, Canonica GW. The role of interleukin 5 in asthma. Expert Rev Clin Immunol. Internet]. 2016 [cited 2018 Mar 22];12:903–905. Available from https://www.tandfonline.com/doi/full/10.1080/1744666X.2016.1208564
- Gleich GJ. Mechanisms of eosinophil-associated inflammation. J Allergy Clin Immunol. Internet]. 2000 [cited 2018 May 17];105:651–663. Available from http://linkinghub.elsevier.com/retrieve/pii/S009167490046762X
- McBrien CN, Menzies-Gow A. The biology of eosinophils and their role in asthma. Front Med. Internet]. 2017 [cited 2018 Oct 1];4:93. Available from http://journal.frontiersin.org/article/10.3389/fmed.2017.00093/full
- Makinde T, Murphy RF, Agrawal DK. The regulatory role of TGF-beta in airway remodeling in asthma. Immunol Cell Biol. 2007;85:348–356. Internet]. [cited 2018 Oct 1].
- Okayama H, Fushimi T, Shimura S, et al. Glucocorticoids suppressed production and gene expression of interleukin-5 by peripheral blood mononuclear cells in atopic patients and normal subjects. J Allergy Clin Immunol. Internet]. 1994 [cited 2018 Sep 28];93:1006–1012. Available from http://www.ncbi.nlm.nih.gov/pubmed/8006305
- Gnanakumaran G, Babu KS. Technology evaluation: mepolizumab, GlaxoSmithKline. Curr Opin Mol Ther. Internet]. 2003 [cited 2018 May 21];5:321–325. Available from http://www.ncbi.nlm.nih.gov/pubmed/12870444
- Walsh GM. Mepolizumab-based therapy in asthma: an update. Curr Opin Allergy Clin Immunol. Internet]. 2015 [cited 2018 May 21];15:392–396. Available from https://insights.ovid.com/crossref?an=00130832-201508000-00019
- Thompson CA. Mepolizumab approved as add-on long-term therapy for severe asthma. Am J Heal Pharm. Internet]. 2015 [cited 2018 May 18];72:2125. Available from http://www.ncbi.nlm.nih.gov/pubmed/26637509
- Flood-Page PT, Menzies-Gow AN, Kay AB, et al. Eosinophil’s role remains uncertain as anti–interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med. Internet]. 2003 [cited 2018 Jun 13];167:199–204. Available from http://www.ncbi.nlm.nih.gov/pubmed/12406833
- NUCALA - HIGHLIGHTS OF PRESCRIBING INFORMATION - 2017 UPDATE [Internet]. 2017. [cited 2018 Aug 13]. Available from: www.fda.gov/medwatch
- Product_Information/human/003860/WC500198037.pdf [Internet]. [ cited 2018 Jul 1]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003860/WC500198037.pdf
- Roufosse F. Targeting the interleukin-5 pathway for treatment of eosinophilic conditions other than asthma. Front Med. Internet]. 2018 [cited 2018 Oct 2];5:49. Available from http://www.ncbi.nlm.nih.gov/pubmed/29682504
- Leckie MJ, Ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet. 2000;356:2144–2148.
- Flood-Page P, Swenson C, Faiferman I, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med. 2007;176:1062–1071.
- Nair P, Pizzichini MMM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009;360:985–993.
- Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360:973–984.
- Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380:651–659.
- Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371:1189–1197.
- Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. Internet]. 2014 [cited 2018 May 21];371:1198–1207. Available from http://www.nejm.org/doi/10.1056/NEJMoa1403290
- Chupp GL, Bradford ES, Albers FC, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. Internet]. 2017 [cited 2018 May 18];5:390–400. Available from http://www.ncbi.nlm.nih.gov/pubmed/28395936
- Lugogo N, Domingo C, Chanez P, et al. Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study. Clin Ther. Internet]. 2016 [cited 2017 Mar 16];38:2058–2070.e1. Available from http://linkinghub.elsevier.com/retrieve/pii/S0149291816304532
- Khatri S, Moore W, Gibson PG, et al. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol. Internet]. 2018 [cited 2018 Nov 15]; Available from. []. : http://www.ncbi.nlm.nih.gov/pubmed/30359681.
- Ortega HG, Yancey SW, Mayer B, et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med. Internet]. 2016 [cited 2016 Sep 22];4:549–556. Available from http://www.ncbi.nlm.nih.gov/pubmed/27177493
- Shimoda T, Odajima H, Okamasa A, et al. Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma. Allergol Int. Internet]. 2017 [cited 2018 May 18];66:445–451. Available from http://www.ncbi.nlm.nih.gov/pubmed/28110896
- Cabon Y, Molinari N, Marin G, et al. Comparison of anti-interleukin-5 therapies in patients with severe asthma: global and indirect meta-analyses of randomized placebo-controlled trials. Clin Exp Allergy. Internet]. 2017 [cited 2018 May 18];47:129–138. Available from http://www.ncbi.nlm.nih.gov/pubmed/27859832
- Yancey SW, Ortega HG, Keene ON, et al. Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma. J Allergy Clin Immunol. Internet]. 2017 [cited 2018 May 18];139:1167–1175.e2. Available from http://www.ncbi.nlm.nih.gov/pubmed/27726946
- He -L-L, Zhang L, Jiang L, et al. Efficacy and safety of anti-interleukin-5 therapy in patients with asthma: A pairwise and Bayesian network meta-analysis. Int Immunopharmacol. Internet]. 2018 [cited 2018 Nov 16];64:223–231. Available from https://linkinghub.elsevier.com/retrieve/pii/S1567576918304594
- Ortega H, Menzies-Gow A, Llanos J-P, et al. Rapid and consistent improvements in morning PEF in patients with severe eosinophilic asthma treated with mepolizumab. Adv Ther. Internet]. 2018 [cited 2018 Nov 16];35:1059–1068. Available from http://link.springer.com/10.1007/s12325-018-0727-8
- Powell C, Milan SJ, Dwan K, et al. Mepolizumab versus placebo for asthma. In: Powell C, editor. Cochrane Database Syst. Rev. Internet]. Chichester, UK: John Wiley & Sons, Ltd; 2015 [cited 2018 May 21]. p. CD010834. Available from http://www.ncbi.nlm.nih.gov/pubmed/26214266
- Farne HA, Wilson A, Powell C, et al. Anti-IL5 therapies for asthma. Cochrane Database Syst Rev. Internet]. 2017 [cited 2018 May 8];9:CD010834.
- Pelaia C, Busceti MT, Solinas S, et al. Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: results of a single-centre observational study. Pulm Pharmacol Ther. Internet]. 2018 [cited 2018 Nov 20];53:1–5. Available from https://linkinghub.elsevier.com/retrieve/pii/S1094553918302128
- Strauss RA, Jawhari N. Mepolizumab in the treatment of severe eosinophilic asthma: results from a physician in the field. Ann Allergy Asthma Immunol. Internet]. 2018 [cited 2018 Nov 20];121:121–123. Available from https://linkinghub.elsevier.com/retrieve/pii/S1081120618303028
- Benjamin MR, Bochner BS, Peters AT. Mepolizumab use: post-approval academic practice experience. Ann Allergy Asthma Immunol. Internet]. 2018 [cited 2018 Nov 20];121:126–128. Available from https://linkinghub.elsevier.com/retrieve/pii/S1081120618302527
- Tran TN, Zeiger RS, Peters SP, et al. Overlap of atopic, eosinophilic, and TH2-high asthma phenotypes in a general population with current asthma. Ann Allergy Asthma Immunol. Internet]. 2016 [cited 2019 Mar 20];116:37–42. Available from http://www.ncbi.nlm.nih.gov/pubmed/26707771
- Nachef Z, Krishnan A, Mashtare T, et al. Omalizumab versus Mepolizumab as add-on therapy in asthma patients not well controlled on at least an inhaled corticosteroid: A network meta-analysis. J Asthma. Internet]. 2018 [cited 2019 Mar 21];55:89–100. Available from https://www.tandfonline.com/doi/full/10.1080/02770903.2017.1306548
- Cockle SM, Stynes G, Gunsoy NB, et al. Comparative effectiveness of mepolizumab and omalizumab in severe asthma: an indirect treatment comparison. Respir Med. Internet]. 2017 [cited 2019 Mar 21];123:140–148. Available from https://linkinghub.elsevier.com/retrieve/pii/S0954611116303377
- Magnan A, Bourdin A, Prazma CM, et al. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment. Allergy. Internet]. 2016 [cited 2017 Mar 16];71:1335–1344.
- Menzella F, Galeone C, Lusuardi M, et al. Near-fatal asthma responsive to mepolizumab after failure of omalizumab and bronchial thermoplasty. Ther Clin Risk Manag. Internet]. 2017 [cited 2018 Apr 10];13:1489–1493. Available from http://www.ncbi.nlm.nih.gov/pubmed/29184413
- Galkin D, Liu MC, Chipps BE, et al. Efficacy and safety of mepolizumab in uncontrolled patients with severe eosinophilic asthma following a switch from omalizumab (OSMO study): exacerbation and safety outcomes. J Allergy Clin Immunol. Internet]. 2018 [cited 2019 Mar 14];141:AB409. Available from https://linkinghub.elsevier.com/retrieve/pii/S0091674917328658
- Albers FC, Liu MC, Chipps BE, et al. Efficacy and safety of mepolizumab in uncontrolled patients with severe eosinophilic asthma following a switch from omalizumab (OSMO study): asthma control, quality of life and lung function outcomes. J Allergy Clin Immunol. Internet]. 2018 [cited 2019 Mar 21];141:AB408. Available from https://linkinghub.elsevier.com/retrieve/pii/S0091674917328646
- Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med. Internet]. 2008 [cited 2019 Jan 16];178:218–224. Available from http://www.ncbi.nlm.nih.gov/pubmed/18480428
- Pepper AN, Renz H, Casale TB, et al. Biologic therapy and novel molecular targets of severe asthma. J Allergy Clin Immunol Pract. Internet]. 2017 [cited 2019 Jan 16];5:909–916. Available from http://www.ncbi.nlm.nih.gov/pubmed/28689841
- Viswanathan R, Busse W. Biologic therapy and asthma. Semin Respir Crit Care Med. Internet]. 2018 [cited 2019 Jan 16];39:100–114. Available from http://www.ncbi.nlm.nih.gov/pubmed/29427990
- Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. Internet]. 2017 [cited 2019 Jan 22];377:936–946. Available from http://www.nejm.org/doi/10.1056/NEJMoa1704064
- U.S. Food and Drug Administration. FDA news release: FDA approves Nucala to treat severe asthma (2015) [Internet]. 2015. [cited 2018 Jul 1]. Available from: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/UCM471031_F
- Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. Internet]. 2015 [cited 2018 Aug 13];3:355–366. Available from http://www.ncbi.nlm.nih.gov/pubmed/25736990
- Open-label extension study to evaluate the long-term safety and efficacy of reslizumab (3.0 mg/kg) as treatment for patients (12 through 75 years of age) with eosinophilic asthma - full text view - ClinicalTrials.gov [Internet]. [cited 2018 Aug 13]. Available from: https://clinicaltrials.gov/ct2/show/NCT01290887?term=NCT01290887&rank=1
- Study of reslizumab in patients with uncontrolled asthma and elevated blood eosinophils - full text view - ClinicalTrials.gov [Internet]. [ cited 2018 Aug 13]. Available from: https://clinicaltrials.gov/ct2/show/NCT02452190?term=NCT02452190&rank=1
- Fda. HIGHLIGHTS OF PRESCRIBING INFORMATION - CINQAIR [Internet]. 2016. [cited 2018 Aug 13]. Available from: www.fda.gov/medwatch
- FDA. HIGHLIGHTS OF PRESCRIBING INFORMATION - FASENRA [Internet]. [ cited 2018 Aug 14]. Available from: www.fda.gov/medwatch
- Patel SS, Casale TB, Cardet JC. Biological therapies for eosinophilic asthma. Expert Opin Biol Ther. Internet]. 2018 [cited 2018 Nov 28];18:747–754. Available from https://www.tandfonline.com/doi/full/10.1080/14712598.2018.1492540
- Busse WW, Katial R, Gossage D, et al. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. J Allergy Clin Immunol. Internet]. 2010 [cited 2018 May 19];125:1237–1244.e2. Available from http://linkinghub.elsevier.com/retrieve/pii/S0091674910006512
- Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. Internet]. 2016 [cited 2018 May 19];388:2115–2127. Available from http://linkinghub.elsevier.com/retrieve/pii/S0140673616313241
- FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. Internet]. 2016 [cited 2018 May 19];388:2128–2141. Available from http://linkinghub.elsevier.com/retrieve/pii/S0140673616313228
- Gleich GJ, Klion AD, Lee JJ, et al. The consequences of not having eosinophils. Allergy. Internet]. 2013 [cited 2019 Mar 18];68:829–835.
- Varricchi G, Galdiero MR, Loffredo S, et al. Eosinophils: the unsung heroes in cancer? Oncoimmunology. Internet]. 2017 [cited 2018 Aug 16];7:e1393134. Available from https://www.tandfonline.com/doi/full/10.1080/2162402X.2017.1393134
- Yancey SW, Keene ON, Albers FC, et al. Biomarkers for severe eosinophilic asthma. J Allergy Clin Immunol. Internet]. 2017 [cited 2018 Nov 29];140:1509–1518. Available from https://linkinghub.elsevier.com/retrieve/pii/S0091674917316512
- Mesnil C, Raulier S, Paulissen G, et al. Lung-resident eosinophils represent a distinct regulatory eosinophil subset. J Clin Invest. Internet]. 2016 [cited 2018 Nov 29];126:3279–3295. Available from https://www.jci.org/articles/view/85664
- Drick N, Seeliger B, Welte T, et al. Anti-IL-5 therapy in patients with severe eosinophilic asthma - clinical efficacyand possible criteria for treatment response. BMC Pulm Med. Internet]. 2018 [cited 2018 Aug 8];18:119. Available from https://bmcpulmmed.biomedcentral.com/articles/10.1186/s12890-018-0689-2
- Ortega H, Li H, Suruki R, et al. Cluster analysis and characterization of response to mepolizumab. A step closer to personalized medicine for patients with severe asthma. Ann Am Thorac Soc. Internet]. 2014 [cited 2018 Aug 13];11:1011–1017. Available from http://www.ncbi.nlm.nih.gov/pubmed/24983709
- Haldar P. Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma. Biologics. Internet]. 2017 [cited 2018 Aug 14];11:81–95. Available from https://www.dovepress.com/patient-profiles-and-clinical-utility-of-mepolizumab-in-severe-eosinop-peer-reviewed-article-BTT
- Mukherjee M, Aleman Paramo F, Kjarsgaard M, et al. Weight-adjusted intravenous reslizumab in severe asthma with inadequate response to fixed-dose subcutaneous mepolizumab. Am J Respir Crit Care Med. Internet]. 2018 [cited 2019 Jan 9];197:38–46. Available from http://www.atsjournals.org/doi/10.1164/rccm.201707-1323OC
- Haldar P, Brightling CE, Singapuri A, et al. Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis. J Allergy Clin Immunol. 2014;133:921–923.